Akero Therapeutics Inc Stock
Akero Therapeutics Inc Stock
The Akero Therapeutics Inc stock is trending slightly upwards today, with an increase of €0.22 (0.470%) compared to yesterday's price.
With 12 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 68 € there is a positive potential of 44.77% for Akero Therapeutics Inc compared to the current price of 46.97 €.
Our community identified positive and negative aspects for Akero Therapeutics Inc stock for the coming years. 2 users see the criterium "Revenue growth" as a plus for the Akero Therapeutics Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Akero Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akero Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | 0.470% | 0.278% | 0.256% | 67.391% | 75.130% | 13.454% | - |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
Comments
Akero Therapeutics (NASDAQ:AKRO) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics (NASDAQ:AKRO) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics (NASDAQ:AKRO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $72.00 price target on the stock.
Show more
Ratings data for AKRO provided by MarketBeat